These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 33384970)
1. Vitamin in the Crosshairs: Targeting Pantothenate and Coenzyme A Biosynthesis for New Antituberculosis Agents. Butman HS; Kotzé TJ; Dowd CS; Strauss E Front Cell Infect Microbiol; 2020; 10():605662. PubMed ID: 33384970 [TBL] [Abstract][Full Text] [Related]
2. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related]
3. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery. de Wet TJ; Warner DF; Mizrahi V Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123 [TBL] [Abstract][Full Text] [Related]
4. Validation of CoaBC as a Bactericidal Target in the Coenzyme A Pathway of Mycobacterium tuberculosis. Evans JC; Trujillo C; Wang Z; Eoh H; Ehrt S; Schnappinger D; Boshoff HI; Rhee KY; Barry CE; Mizrahi V ACS Infect Dis; 2016 Dec; 2(12):958-968. PubMed ID: 27676316 [TBL] [Abstract][Full Text] [Related]
5. Vitamins Based Novel Target Pathways/Molecules as Possible Emerging Drug Targets for the Management of Tuberculosis. Sharma A; Jain K; Flora SJS Med Chem; 2018; 14(3):212-224. PubMed ID: 29110620 [TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
8. The Methylerythritol Phosphate Pathway: Promising Drug Targets in the Fight against Tuberculosis. Wang X; Dowd CS ACS Infect Dis; 2018 Mar; 4(3):278-290. PubMed ID: 29390176 [TBL] [Abstract][Full Text] [Related]
9. Targeting Evans JC; Murugesan D; Post JM; Mendes V; Wang Z; Nahiyaan N; Lynch SL; Thompson S; Green SR; Ray PC; Hess J; Spry C; Coyne AG; Abell C; Boshoff HIM; Wyatt PG; Rhee KY; Blundell TL; Barry CE; Mizrahi V ACS Infect Dis; 2021 Jun; 7(6):1666-1679. PubMed ID: 33939919 [TBL] [Abstract][Full Text] [Related]
10. Chemical Validation of Mycobacterium tuberculosis Phosphopantetheine Adenylyltransferase Using Fragment Linking and CRISPR Interference. El Bakali J; Blaszczyk M; Evans JC; Boland JA; McCarthy WJ; Fathoni I; Dias MVB; Johnson EO; Coyne AG; Mizrahi V; Blundell TL; Abell C; Spry C Angew Chem Int Ed Engl; 2023 Apr; 62(17):e202300221. PubMed ID: 36757665 [TBL] [Abstract][Full Text] [Related]
11. Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD. Gopal P; Nartey W; Ragunathan P; Sarathy J; Kaya F; Yee M; Setzer C; Manimekalai MSS; Dartois V; Grüber G; Dick T ACS Infect Dis; 2017 Nov; 3(11):807-819. PubMed ID: 28991455 [TBL] [Abstract][Full Text] [Related]
12. Assessment of Mycobacterium tuberculosis pantothenate kinase vulnerability through target knockdown and mechanistically diverse inhibitors. Reddy BK; Landge S; Ravishankar S; Patil V; Shinde V; Tantry S; Kale M; Raichurkar A; Menasinakai S; Mudugal NV; Ambady A; Ghosh A; Tunduguru R; Kaur P; Singh R; Kumar N; Bharath S; Sundaram A; Bhat J; Sambandamurthy VK; Björkelid C; Jones TA; Das K; Bandodkar B; Malolanarasimhan K; Mukherjee K; Ramachandran V Antimicrob Agents Chemother; 2014 Jun; 58(6):3312-26. PubMed ID: 24687493 [TBL] [Abstract][Full Text] [Related]
13. The implication of Mycobacterium tuberculosis-mediated metabolism of targeted xenobiotics. Singh V; Dziwornu GA; Chibale K Nat Rev Chem; 2023 May; 7(5):340-354. PubMed ID: 37117810 [TBL] [Abstract][Full Text] [Related]
14. Natural products against key Mycobacterium tuberculosis enzymatic targets: Emerging opportunities for drug discovery. Cazzaniga G; Mori M; Chiarelli LR; Gelain A; Meneghetti F; Villa S Eur J Med Chem; 2021 Nov; 224():113732. PubMed ID: 34399099 [TBL] [Abstract][Full Text] [Related]
15. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents. Keri RS; Sasidhar BS; Nagaraja BM; Santos MA Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067 [TBL] [Abstract][Full Text] [Related]
16. Strategies to Combat Multi-Drug Resistance in Tuberculosis. Singh V; Chibale K Acc Chem Res; 2021 May; 54(10):2361-2376. PubMed ID: 33886255 [TBL] [Abstract][Full Text] [Related]
17. Inhibiting Mycobacterium tuberculosis CoaBC by targeting an allosteric site. Mendes V; Green SR; Evans JC; Hess J; Blaszczyk M; Spry C; Bryant O; Cory-Wright J; Chan DS; Torres PHM; Wang Z; Nahiyaan N; O'Neill S; Damerow S; Post J; Bayliss T; Lynch SL; Coyne AG; Ray PC; Abell C; Rhee KY; Boshoff HIM; Barry CE; Mizrahi V; Wyatt PG; Blundell TL Nat Commun; 2021 Jan; 12(1):143. PubMed ID: 33420031 [TBL] [Abstract][Full Text] [Related]
18. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. Kiran D; Podell BK; Chambers M; Basaraba RJ Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950 [TBL] [Abstract][Full Text] [Related]
19. Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon. Bhat ZS; Rather MA; Maqbool M; Ahmad Z Biomed Pharmacother; 2018 Jul; 103():1733-1747. PubMed ID: 29864964 [TBL] [Abstract][Full Text] [Related]
20. Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosis. Bhat ZS; Rather MA; Maqbool M; Lah HU; Yousuf SK; Ahmad Z Biomed Pharmacother; 2017 Nov; 95():1520-1534. PubMed ID: 28946393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]